Dr Reddy’s Laboratories

The acquisition will complement DRL's US retail prescription pharmaceutical business with limited competition products

Firm says sustained focus on improving productivity has also helped boost profits; DRL is now bullish on its biosimilars and hopes to start filing for them in US in the coming quarters

Stock market LIVE: As per rollover data, the Nifty index has, so far, witnessed rollover in-line with the last three months' averages. However, slight declines in roll cost indicates a capped upside

Stocks to Watch today: Wipro, after market hours on Friday, reported a consolidated net profit of Rs 3,052 crore for October-December FY23, an increase of 2.8 per cent year-on-year (YoY)

Dr. Reddy's plans to roll out a unique Patient Assistance Programme to support long-term therapy of the patients on Primcyv

After the anti-diabetic market, India's cardiac market in for a shake-up

Change effective from Dec 19, but adjustment will take place on Dec 16. After DRL's deletion, Sun Pharma will be the only healthcare stock in the index

Dr Reddy's Laboratories has earmarked a capex of around Rs 1,500 crore for FY23 with major part of it slated to go into building capacities for its biosimilar and injectable businesses, according to CFO Parag Agarwal. The Hyderabad-based drug major also plans to utilise the capital for adding capacities to existing plants, firm up R&D activities and further invest in digitisation projects. "The capex for the full year is likely to be around Rs 1,500 crore in that range, and a lot of this capex is towards building capacity for our biosimilar business and for our injectable business," the chief financial officer said in an analyst call. He was replying to a query about the company's capex plans for ongoing financial year. "When we say capex, obviously, it is not all going into building new plants. So, there will be several additions to existing plants, there will be maintenance capex, there will be capex on digitalisation projects, on R&D facility. So, it is all put together," .

Excluding the strong US show led by Revlimid, Q2 was a mixed bag

Stock market wrap: Reliance alone contributed 231 points to the 30-share benchmark. Maruti, M&M and NTPC were the other major gainers. The Metal and IT sector witnessed selling pressure.

While domestic market demand is strong, analysts expect higher raw material and freight costs to affect business in US, other countries; healthy YoY growth seen in hospitals and diagnostics

Company left with low-margin brands in India after selling profitable ones

Candle Partners study shows that from the peak of 30% of gross block in FY16, the capex is down to 9-10% of gross block

If added, Adani Green will be the first stock from the group in Sensex. After the inclusion of Adani Enterprises by September-end, Nifty will have two Adani group constituents

Among the companies that are working with ICMR are Serum Institute of India (SII), Reliance Life Sciences, Dr Reddy's Laboratories, and Biological E

Plans afoot to seek regulator nod for universal boosters

The DRL stock was down marginally (0.73 per cent) to Rs 4,254 on the BSE on Thursday

Bajaj Finserv on Thursday reported a 57 per cent jump in net profit at Rs 1,309 crore in the first quarter ended June 30, on healthy earnings by its subsidiary companies.

Dr Reddy's Labs Q1 results preview: Analysts said that despite pricing pressures in the US, the company is likely to have recorded steady growth in this segment due to a ramp-up of new products.

The US would continue to remain an important geography, but the firm says it hopes to double its revenues from China and grow revenues five-fold in Brazil in the next five years